MNPR-201 (GPX-150 5-imino-13-deoxydoxorubicin) is a proprietary analog of doxorubicin. Doxorubicin is used to treat adult and pediatric solid and blood (hematologic) cancers including breast, gastric, ovarian and bladder cancer, soft tissue sarcomas, leukemias and lymphomas. Doxorubicin is often used in combination with other cancer drugs and is frequently used to treat metastatic disease. However, reaching optimal clinical efficacy of doxorubicin has been limited historically by the risk of patients developing irreversible, potentially life-threatening cardiotoxicity. MNPR-201 (GPX-150) has been engineered specifically to retain the anticancer activity of doxorubicin while minimizing toxic effects on the heart. Since clinical data has demonstrated the anti-cancer benefit of higher doses of doxorubicin administered for longer periods of time, along with the potential to combine a non-cardiotoxic analog of doxorubicin with other anticancer agents, we believe that there is a large market opportunity in a broad spectrum of cancer types for MNPR-201 (GPX-150).
The antitumor effects of MNPR-201 (GPX-150) are mediated through stabilization of the topoisomerase II complex after a DNA strand break leading to apoptosis (cell death) through a mechanism similar to doxorubicin and other anthracycline drugs. Inhibiting the topoisomerase IIα isoform is desired for the anti-cancer effect, while inhibiting the topoisomerase IIβ isoform has been demonstrated to mediate, at least in part, the cardiotoxicity associated with all anthracycline drugs currently used in the clinic. MNPR-201 (GPX-150) is substantially more selective than doxorubicin for inhibiting topoisomerase IIα versus topoisomerase IIβ. This selectivity may at least partly explain the lack of cardiotoxicity that MNPR-201 (GPX-150) has demonstrated when compared to doxorubicin in studies to date. Thus, based on its selectivity for topoisomerase IIα, MNPR-201 (GPX-150) represents the first-ever anthracycline-based targeted cancer therapeutic.
Learn more about the clinical studies that support the safety and efficacy of MNPR-201 (GPX-150).